Table 2.
Regimens for first-line and second-line treatment
| First-line treatment | |
| Group A (n = 25) | |
| 5-fluorouracil + radiation | 5 |
| 5-fluorouracil ia + radiation | 2 |
| 5-fluorouracil + cisplatin + radiation | 1 |
| 5-fluorouracil ia | 1 |
| 5-fluorouracil + doxorubicin + mitomycin C ia | 1 |
| 5-fluorouracil + cisplatin | 3 |
| 5-fluorouracil + doxorubicin + mitomycin C | 1 |
| Uracil-tegafur | 2 |
| Gemcitabine | 9 |
| Group B (n = 54) | |
| 5-fluorouracil + radiation | 2 |
| 5-fluorouracil ia + radiation | 2 |
| Uracil-tegafur + radiation | 1 |
| 5-fluorouracil | 1 |
| 5-fluorouracil + doxorubicin + mitomycin C | 2 |
| Gemcitabine | 25 |
| S-1 | 20 |
| Gemcitabine + cisplatin | 1 |
| Group C (n = 107) | |
| Gemcitabine + S-1 | 62 |
| Gemcitabine | 44 |
| S-1 | 1 |
| Second-line treatment | |
| Group A (n = 6) | |
| Gemcitabine | 2 |
| Gemcitabine ia | 1 |
| 5-fluorouracil + radiation | 1 |
| S-1 | 1 |
| Uracil-tegafur | 1 |
| Group B (n = 27) | |
| Gemcitabine | 14 |
| S-1 | 9 |
| S-1 + interferon-α | 1 |
| 5-fluorouracil | 2 |
| Mitomycin C | 1 |
| Group C (n = 51) | |
| Gemcitabine + cisplatin | 28 |
| Gemcitabine | 6 |
| S-1 | 13 |
| Cisplatin ia | 1 |
| 5-fluorouracil + interferon-α | 1 |
| Irinotecan | 1 |
| Uracil-tegafur | 1 |